Anaptys Announces Participation in November and December Investor Conferences

ANAB 11.05.2024

Full Press ReleaseSEC FilingsOur ANAB Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.07.2025 - Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.11.2024 - Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Recent Filings

  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.18.2024 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors

SAN DIEGO,Nov. 05, 2024(GLOBE NEWSWIRE) --AnaptysBio, Inc.(Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced thatDaniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Guggenheim'sInaugural Healthcare Innovation Conference,Boston, MA

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time –Wednesday, Nov. 13, 2024at1:30pm ET/10:30am PT

Stifel 2024 Healthcare Conference,New York, NY

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time –Tuesday, Nov. 19, 2024at1:50pm ET/10:50am PT

Piper Sandler 36th Annual Healthcare Conference,New York, NY

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time –Tuesday, Dec. 3, 2024at2:30pm ET/11:30am PT

7th AnnualEvercore HealthCONx Conference,Coral Gables, FL

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time –Wednesday, Dec. 4, 2024at1:45pm ET/10:45am PT

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website athttp://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes two programs targeting co-inhibitory receptors: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other antibodies in its portfolio, including ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli(dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visitwww.AnaptysBio.comor follow us onLinkedInandX.

Contact:Nick MontemaranoSenior Director, Investor Relations andStrategic Communications858.732.0178investors@anaptysbio.com

Primary Logo

Source: AnaptysBio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com